Notably, in renal cell carcinoma, METTL14 and IGF2BP2 collaboratively regulate tumor angiogenesis and metastasis while also managing drug resistance in cancer cells during clinical treatment. The gene discussed is IGF2BP2; the disease is neoplasm.